Publication:
Modifiers of the Effectiveness of MS Immunotherapies

dc.contributor.authorKalincik, T.
dc.contributor.authorMalpas, C.
dc.contributor.authorSharmin, S.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E. K.
dc.contributor.authorTrojano, M.
dc.contributor.authorVan Pesch, V.
dc.contributor.authorIDFerraro, Diana/0000-0003-4818-3806
dc.contributor.authorIDMcCombe, Pamela/0000-0003-2704-8517
dc.date.accessioned2020-06-21T12:26:02Z
dc.date.available2020-06-21T12:26:02Z
dc.date.issued2019
dc.departmentOMÜen_US
dc.department-temp[Kalincik, T. -- Malpas, C. -- Sharmin, S.] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia -- [Kalincik, T. -- Malpas, C. -- Sharmin, S.] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia -- [Horakova, D.en_US
dc.description35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENen_US
dc.description.abstracten_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltden_US
dc.description.sponsorshipNational Medical and Research Council; Biogen Registry Fellowshipen_US
dc.description.sponsorshipThis study received support from National Medical and Research Council and Biogen Registry Fellowship.en_US
dc.identifier.endpage793en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage791en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10633
dc.identifier.volume25en_US
dc.identifier.wosWOS:000485303103220
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleModifiers of the Effectiveness of MS Immunotherapiesen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files